NEW YORK, NY (Jan. 24, 2022)--An experimental drug, first tried at Columbia University Irving Medical Center as a last-ditch effort to help a 25-year-old woman withjuvenile ALS, is now being tested in ALS patients in a global, phase 3 clinical trial, based on promising results from a new study at Columbia.

The study found that the druginformally named jacifusenlowered levels of FUS, a toxic protein in the womans neurons and in mice with the disease.

The clinical trial will be pivotal in determining if the drug can slow the progression of the disease.

Though the drug was possibly too little, too late, to help the young woman who first received it, the study found that it had a profound effect, virtually eliminating the toxic proteins in the central nervous system and reducing the burden of FUS pathology dramatically, says study leader Neil Shneider, MD, PhD, the Claire Tow Associate Professor of Motor Neuron Disorders in the Department of Neurology and director of the Eleanor and Lou Gehrig ALS Center at Columbia University Vagelos College of Physicians and Surgeons.

Together with our animal data, this study suggests that the drug has the potential to delay or prevent ALS caused by mutant FUS before symptoms appear or slow clinical progression after disease onset.

The story of Jacifusen

Jacifusen gets its name from Jaci Hermstad, the first person to receive the drug, but it was already in development before Jaci was diagnosed with ALS.

ALS is usually associated with adults, but a rare and aggressive form of the disease can affect individuals, like Jaci, in their teens or 20s. The disease attacks the patients motor neurons, which control the bodys muscles, until the patient can no longer move or breathe unassisted.

Several years ago, researchers discovered that most adolescents and young adults with ALS have mutations in a gene calledFUS.

In a study of a series of mouse models with ALS-relatedFUSmutations published in 2016, and in another series in the current study, Shneider found that the mutant FUS protein is toxic to motor neurons, suggesting that lowering FUS levels by silencing the gene that makes the protein might protect neurons in ALS patients with the mutation.

In 2018, Shneider met Jaci, a young woman from Iowa whose identical twin sister had died of ALS caused by a genetic mutation in theFUSgene.Soon after, Jaci began to show signs and symptoms of ALS. Shneider immediately reached out to Ionis Pharmaceuticalsa leading developer of antisense therapeuticslooking for a drug that shuts down production of the FUS protein, which might slow the progression of Jacis disease. This led to the identification of ION363, a compound that effectively lowered FUS levels in the mouse brain and spinal cord and prevented disease onset in the mouse model of FUS-related ALS. However, this drughad never been tested in humans.

With remarkable speed, Shneider won special permission from the Food and Drug Administration to give the drug to Jaci through its compassionate use program, which makes experimental treatments available to seriously ill patients outside of clinical trials. There was no time to waste. People with these mutations usually die within a year of diagnosis, Shneider says.

Jaci received the first of several doses of the drug in 2019. We saw a significant slowdown in her functional decline, suggesting that the drug was working as intended, but sadly, her disease was already advanced by the time she began the treatment and she died about a year later, Shneider says.

New study suggests jacifusen eliminates toxic proteins

In his new study, published Jan. 24, 2022, in Nature Medicine, Shneider found that a single infusion of jacifusen at birth in a mouse model effectively silenced theFUSgene, reduced FUS protein levels in the brain and spinal cord, and delayed motor neuron degeneration in the miceall with no apparent side effects.

In Jaci, jacifusen also caused profound changes in the brain. Examination of Jacis brain tissue, donated by Jaci and the Hermstad family, found that treatment with the eponymous drug markedly reduced FUS protein clumpsa hallmark of the diseasein her brain cells. At a cellular level, jacifusen was extremely effective at doing what we hoped it would do, he said.

The findings, along with encouraging signs from 10 other patients who received jacifusen under the compassionate use program, convinced Ionis to sponsor a pivotalphase 3 clinical trialatColumbia and multiple other sites in the United States, Europe and Asia. The trial, led by Shneider, will enroll at least 64 patients.

This trial will determine if jacifusen is safe, and if it can effectively slow disease progression in symptomatic FUS-ALS patients.If approved, jacifusen would be the first treatment for this highly aggressive form of early-onset ALS, Shneider says.

Future studies will determine if jacifusen works if given to people with ALS-associated FUS mutationsbeforethey become symptomatic, as it did in the mouse studies.

This study is an example of truly personalized medicine in the 21stcentury.

More information

The study was published online [January 24, 2022] inNature Medicine.

The study is titled, Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis. The other contributors are:Vladislav A. Korobeynikov(CUIMC), Alexander K. Lyashchenko(CUIMC),Beatriz Blanco-Redondo(Columbia andLeipzig University, Leipzig, Germany), and Paymaan Jafar-nejad (Ionis Pharmaceuticals).

The study was supported by grants fromthe National Institute of Neurological Disorders and Stroke (R01NS106236) and the Tow Foundation. Support for the FUS ASO (ION363) expanded access program was provided by Project ALS and the ALS Association. Additional funding was provided by Nancy Perlman and Tom Klingenstein and the Judith and Jean Pape Adams Charitable Foundation.

The authors declare no competing interests.

###

Columbia University Irving Medical Center provides international leadership in basic, preclinical, and clinical research; medical and health sciences education; and patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the Vagelos College of Physicians and Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. Columbia University Irving Medical Center is home to the largest medical research enterprise in New York City and State and one of the largest faculty medical practices in the Northeast. For more information, visit cuimc.columbia.edu or columbiadoctors.org.

Experimental study

People

Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis

24-Jan-2022

The authors declare no competing interests.

Visit link:

Promising ALS therapy moves closer to clinic - EurekAlert